Neogenomics (NEO) EPS (Weighted Average and Diluted): 2009-2025
Historic EPS (Weighted Average and Diluted) for Neogenomics (NEO) over the last 17 years, with Sep 2025 value amounting to -$0.21.
- Neogenomics' EPS (Weighted Average and Diluted) fell 50.00% to -$0.21 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.88, marking a year-over-year decrease of 44.26%. This contributed to the annual value of -$0.62 for FY2024, which is 11.43% up from last year.
- Latest data reveals that Neogenomics reported EPS (Weighted Average and Diluted) of -$0.21 as of Q3 2025, which was up 40.00% from -$0.35 recorded in Q2 2025.
- In the past 5 years, Neogenomics' EPS (Weighted Average and Diluted) ranged from a high of $0.59 in Q2 2021 and a low of -$0.40 during Q1 2022.
- In the last 3 years, Neogenomics' EPS (Weighted Average and Diluted) had a median value of -$0.19 in 2023 and averaged -$0.19.
- The largest annual percentage gain for Neogenomics' EPS (Weighted Average and Diluted) in the last 5 years was 1,083.33% (2021), contrasted with its biggest fall of 525.00% (2021).
- Over the past 5 years, Neogenomics' EPS (Weighted Average and Diluted) (Quarterly) stood at -$0.35 in 2021, then spiked by 48.57% to -$0.18 in 2022, then skyrocketed by 38.89% to -$0.11 in 2023, then declined by 9.09% to -$0.12 in 2024, then crashed by 50.00% to -$0.21 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.21 for Q3 2025, versus -$0.35 for Q2 2025 and -$0.20 for Q1 2025.